A single-dose live-attenuated Zika Virus vaccine with controlled infection rounds that protects against vertical transmission
Kum, Dieudonné B
Muruato, Antonio E
Medeiros, Daniele Barbosa de Almeida
Nunes, Bruno Tardelli Diniz
Rossi, Shannan L
Weaver, Scott C
Vasconcelos, Pedro Fernando da Costa
Zika virus (ZIKV) infection of the mother during pregnancy causes devastating Zika congenital syndrome in the offspring. A ZIKV vaccine with optimal safety and immunogenicity for use in pregnant women is critically needed. Toward this goal, we have developed a single-dose live-attenuated vaccine candidate that infects cells with controlled, limited infection rounds. The vaccine contains a 9-amino-acid deletion in the viral capsid protein and replicates to titers of > 10 6 focus-forming units (FFU)/mL in cells expressing the full-length capsid protein. Immunization of A129 mice with one dose (10 5 FFU) did not produce viremia, but elicited protective immunity that completely prevented viremia, morbidity, and mortality after challenge with an epidemic ZIKV strain (10 6 PFU). A single-dose vaccination also fully prevented infection of pregnant mice and maternal-to-fetal transmission. Intracranial injection of the vaccine (10 4 FFU) to 1-day-old mice did not cause any disease or death, underscoring the safety of this vaccine candidate.
ReferênciaXIE, Xuping et al. A single-dose live-attenuated Zika Virus vaccine with controlled infection rounds that protects against vertical transmission. Cell Host and Microbe, v. 24, n. 4, p. 487-499, Oct. 2018.
DeCsVacinas / imunologia
Zika virus / patogenicidade
Vacinas / antagonistas & inibidores
Infecção pelo Zika virus
Proteínas do Capsídeo
Estudos de Validação